{"count":80,"next":"http://api.gregory-ms.com/trials/source/12/?page=5","previous":"http://api.gregory-ms.com/trials/source/12/?page=3","results":[{"title":"Osmotin Plant Protein for Progressive Multiple Sclerosis","summary":"Condition: Progressive Multiple Sclerosis
Intervention: Dietary Supplement: Osmotin
Sponsors: Ospedale Policlinico San Martino; Italian Multiple Sclerosis Foundation; S. Andrea Hospital
Recruiting","link":"http://classic.clinicaltrials.gov/ct2/show/NCT05937802?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","published_date":"2023-07-10T16:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2023-07-10T12:20:42.339666Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"National Registry of Rare Kidney Diseases","summary":"Conditions: Adenine Phosphoribosyltransferase Deficiency; AH Amyloidosis; AHL Amyloidosis; AL Amyloidosis; Alport Syndrome; Atypical Hemolytic Uremic Syndrome; Autoimmune Distal Renal Tubular Acidosis; Autosomal Recessive Proximal Renal Tubular Acidosis; Autosomal Recessive Distal Renal Tubular Acidosis; Autosomal Dominant Polycystic Kidney Disease; Autosomal Recessive Polycystic Kidney Disease; Bartter Syndrome; BK Nephropathy; C3 Glomerulopathy With Monoclonal Gammopathy; C3 Glomerulopathy; Calciphylaxis; Crystalglobulinaemia; Crystal-storing Histiocytosis; Cystinosis; Cystinuria; Dense Deposit Disease; Dent Disease; Denys-Drash Syndrome; Dominant Hypophosphataemia With Nephrolithiasis and/or Osteoporosis; Drug Induced Fanconi Syndrome; Drug-Induced Hypomagnesemia; Drug-Induced Nephrogenic Diabetes Insipidus; Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy; Fabry Disease; Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis; Familial Primary Hypomagnesemia With Hypocalcuria; Familial Primary Hypomagnesaemia With Normocalciuria; Familial Renal Glucosuria; Fanconi Renotubular Syndrome 1; Fanconi Renotubular Syndrome 2; Fanconi Renotubular Syndrome 3; Fibrillary Glomerulonephritis; Fibromuscular Dysplasia; Focal Segmental Glomerulosclerosis; Generalised Pseudohypoaldosteronism Type 1; Gitelman Syndrome; Heavy-Metal-Induced Fanconi Syndrome; Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes; Hereditary Renal Hypouricemia; Hereditary Hypophosphatemic Rickets With Hypercalciuria; Hyperuricaemic Nephropathy; IgA Nephropathy; Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits; Inherited Renal Cancer Syndromes; Intracapillary Monoclonal IgM Without Cryoglobulin; Intraglomerular/Capillary Lymphoma/Leukaemia; Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type; Liddle Syndrome; Light Chain Cast Nephropathy; Light Chain Proximal Tubulopathy Without Crystals; Light Chain Proximal Tubulopathy With Crystals; Lowe Syndrome; Membranous Nephropathy; Membranoproliferative Glomerulonephritis; Medullary Cystic Kidney Disease; Minimal Change Nephropathy; Mitochondrial Disease Of The Kidney; Monoclonal Immunoglobulin Deposition Disease; Nail Patella Syndrome; Nephrogenic Diabetes Insipidus; Nephrogenic Syndrome of Inappropriate Antidiuresis; Nephronophthisis; Primary Hypomagnesemia With Secondary Hypocalcemia; Primary Hyperoxaluria; Proliferative Glomerulonephritis With Monoclonal IgG Deposits; Proximal Tubulopathy Without Crystals; Pseudohypoaldosteronism Type 1, 2A-2E; Pure Red Cell Aplasia; Retroperitoneal Fibrosis; Sickle Cell Nephropathy; Shiga Toxin Associated Haemolytic Uraemic Syndrome; Steroid Resistant Nephrotic Syndrome; Steroid-Sensitive Nephrotic Syndrome; Thin Basement Membrane Nephropathy; Thrombotic Microangiopathy With Monoclonal Gammopathy; Type 1 Cryoglobulinaemic Glomerulonephritis; Tuberous Sclerosis; Unclassified Monoclonal Gammopathy Of Renal Significance; Vasculitis\n
Sponsors: UK Kidney Association\n
Recruiting","link":"https://clinicaltrials.gov/study/NCT06065852?cond=Multiple+Sclerosis","published_date":"2023-10-04T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2023-10-04T16:22:33.999871Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy","summary":"Conditions: Mesial Temporal Lobe Epilepsy\n
Interventions: Genetic: AAV9-hSyn1-miGRIK2\n
Sponsors: uniQure France SAS\n
Not yet recruiting","link":"https://clinicaltrials.gov/study/NCT06063850?cond=Multiple+Sclerosis","published_date":"2023-10-03T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2023-10-04T00:42:29.415068Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence","summary":"Conditions: Multiple Sclerosis\n
Interventions: Other: Stoller's Afferent Nerve Stimulation (SANS)\n
Sponsors: Istituto Auxologico Italiano\n
Recruiting","link":"https://clinicaltrials.gov/study/NCT06314412?cond=Multiple+Sclerosis","published_date":"2024-03-18T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2024-03-28T14:55:24.814394Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"Social and Moral Cognition in Multiple Sclerosis","summary":"Conditions: Multiple Sclerosis\n
Interventions: Other: Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment; Other: MS questionnaire; Other: MONTREAL COGNITIVE ASSESSMENT (MoCA) test\n
Sponsors: Lille Catholic University\n
Recruiting","link":"https://clinicaltrials.gov/study/NCT06318923?cond=Multiple+Sclerosis","published_date":"2024-03-19T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2024-03-28T14:55:24.688124Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease","summary":"Conditions: Motor Neuron Disease, Amyotrophic Lateral Sclerosis; Motor Neuron Disease Progressive Spinal Muscle Atrophy; Primary Lateral Sclerosis; Multiple Sclerosis; Postpoliomyelitis Syndrome\n
Interventions: Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)\n
Sponsors: University of Dublin, Trinity College; Motor Neurone Disease Association, UK; Irish Research Council, IE; Health Research Board, IE; Research Motor Neurone, IE; Thierry Latran Foundation, FR; ALS Association, USA\n
Recruiting","link":"https://clinicaltrials.gov/study/NCT06320444?cond=Multiple+Sclerosis","published_date":"2024-03-20T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2024-03-28T14:55:30.212160Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"Blood Flow Restriction Training in Multiple Sclerosis","summary":"Conditions: MS\n
Interventions: Other: strengthening ex with BFR training; Other: strengthening ex\n
Sponsors: Cairo University\n
Recruiting","link":"https://clinicaltrials.gov/study/NCT06143930?cond=Multiple+Sclerosis","published_date":"2023-11-22T05:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2023-11-22T13:43:10.591844Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"ADAs to Alemtuzumab","summary":"Conditions: Multiple Sclerosis\n
Interventions: Drug: Alemtuzumab\n
Sponsors: Queen Mary University of London\n
Active, not recruiting","link":"https://clinicaltrials.gov/study/NCT06310343?cond=Multiple+Sclerosis","published_date":"2024-03-15T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2024-03-22T13:17:17.400175Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[{"category_id":2,"category_description":"LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/","category_name":"Alemtuzumab","category_slug":"alemtuzumab","category_terms":["alemtuzumab","lemtrada"],"article_count":113}]},{"title":"the EXPOSITION Study","summary":"Conditions: Multiple Sclerosis, Relapsing-Remitting; Environmental Exposure; Lifestyle Factors\n
Sponsors: University of Pavia; National Research Council (Consiglio Nazionale delle Ricerche); IRCCS National Neurological Institute \"C. Mondino\" Foundation\n
Not yet recruiting","link":"https://clinicaltrials.gov/study/NCT06325358?cond=Multiple+Sclerosis","published_date":"2024-03-22T04:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2024-03-28T14:55:25.137506Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]},{"title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","summary":"Condition: SARS-CoV InfectionInterventions: Biological: COMIRNATY - BioNTech Manufacturing GmbH; Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH; Biological: COVID-19 Vaccine AstraZeneca suspension for injectionSponsors : Jens D Lundgren, MD; Ministry of the Interior and Health, DenmarkRecruiting ","link":"https://clinicaltrials.gov/ct2/show/NCT04760132?term=biontech&sfpd_d=14&sel_rss=new14","published_date":"2021-02-18T17:00:00Z","source":"Clinical Trials.gov","publisher":null,"container_title":null,"relevant":null,"ml_prediction_gnb":null,"ml_prediction_lr":null,"ml_prediction_lsvc":null,"discovery_date":"2021-02-27T01:00:00Z","noun_phrases":null,"doi":null,"access":null,"takeaways":null,"categories":[]}]}